Develops AI-driven immunotherapies for cancer and infectious diseases, focusing on precision medicine and personalized treatment approaches.
Evaxion Biotech A/S is a clinical-stage biotechnology company specializing in the development of cutting-edge immunotherapies powered by artificial intelligence. Focused on addressing a range of diseases including cancers, bacterial infections, and viral illnesses, Evaxion Biotech is advancing several promising programs. These include EVX-01, currently in Phase IIb clinical trials for metastatic melanoma, and EVX-02, a DNA-based immunotherapy undergoing Phase IIa trials for adjuvant melanoma treatment. Additionally, the company is developing EVX-03, another DNA-based therapy targeting various cancers. Evaxion Biotech's pipeline also features EVX-B1, EVX-B2, and EVX-V1 vaccines in pre-clinical stages, aimed at combatting bacterial and viral diseases.
Founded in 2008 and headquartered in Hørsholm, Denmark, Evaxion Biotech leverages its innovative AI-driven approach to pioneer novel treatments in the field of immunotherapy. With a commitment to scientific excellence and therapeutic advancement, the company continues to expand its portfolio of potentially transformative therapies. Evaxion Biotech's strategic location in Denmark, a hub of biotechnological innovation, supports its mission to develop groundbreaking solutions that address critical medical challenges on a global scale.
Through its dedicated research and development efforts, Evaxion Biotech remains at the forefront of biopharmaceutical innovation. By harnessing the power of artificial intelligence, the company aims to revolutionize the treatment landscape for cancers, infectious diseases, and beyond, striving to improve patient outcomes and redefine standards of care worldwide.